Go Pro
→ Elon's Terrifying Warning: America Is '1,000% Going Bankrupt' (From American Hartford Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$255.41
$246.03
$175.19
▼
$282.15
$15.93B0.39514,876 shs325,549 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.48
$75.69
$45.40
▼
$93.42
$16.51B0.962.08 million shs2.15 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$54.07
$54.17
$33.76
▼
$57.57
$13.59B0.442.64 million shs3.55 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$27.07
$28.47
$6.25
▼
$34.39
$3.92B1.162.27 million shs3.23 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+4.71%-5.56%+7.01%+33.38%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.48%-1.64%+30.61%+81.37%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+1.96%-4.30%+8.77%+43.35%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
0.00%-0.40%-12.85%+15.29%+309.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$255.41
$246.03
$175.19
▼
$282.15
$15.93B0.39514,876 shs325,549 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.48
$75.69
$45.40
▼
$93.42
$16.51B0.962.08 million shs2.15 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$54.07
$54.17
$33.76
▼
$57.57
$13.59B0.442.64 million shs3.55 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$27.07
$28.47
$6.25
▼
$34.39
$3.92B1.162.27 million shs3.23 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+4.71%-5.56%+7.01%+33.38%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.48%-1.64%+30.61%+81.37%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+1.96%-4.30%+8.77%+43.35%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
0.00%-0.40%-12.85%+15.29%+309.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.06
Buy$296.1215.94% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.82
Moderate Buy$97.3315.21% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.26
Hold$49.79-7.92% Downside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.75
Moderate Buy$42.1555.72% Upside

Current Analyst Ratings Breakdown

Latest TNGX, BBIO, ASND, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$56.00 ➝ $52.00
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$52.00
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$47.00 ➝ $51.00
8/3/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$55.00
8/3/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/24/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B+) ➝ Buy (B)
7/23/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$256.00 ➝ $275.00
7/23/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$50.00 ➝ $53.00
7/22/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
7/17/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$36.00 ➝ $40.00
7/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$82.00 ➝ $93.00
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.56N/AN/A($2.97) per share-86.00
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M32.89N/AN/A($10.77) per share-7.84
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B5.86$3.03 per share17.86$8.06 per share6.71
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M62.77N/AN/A$2.57 per share10.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6729.4622.15N/A57.87%N/A-8.37%8/13/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A1,206.86N/A-124.42%N/A-65.81%8/10/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1817.0014.611.6335.33%42.17%31.76%N/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$0.83N/AN/AN/AN/A-41.54%-33.44%8/11/2026 (Estimated)

Latest TNGX, BBIO, ASND, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71N/AN/AN/A$376.75 millionN/A
8/11/2026Q2 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.3172N/AN/AN/A$1.56 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756N/AN/AN/A$220.91 millionN/A
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
5/13/2026Q1 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.32-$0.32N/A-$0.32$0.58 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
27.38
27.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077251.35 million244.82 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
90144.65 million135.25 millionOptionable

Recent News About These Companies

Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure
August 9 at 8:47 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TNGX-Q/pressreleases/3728512/tango-therapeutics-announces-executive-chair-barbara-webers-departure/
The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX
August 9 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-boosts-holdings-in-tango-therapeutics-inc-tngx-2026-08-09/
Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?
August 7 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tango-therapeutics-nasdaqtngx-trading-down-61-whats-next-2026-08-07/
Tango Therapeutics Announces Executive Chair Transition
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340879/0/en/tango-therapeutics-announces-executive-chair-transition.html
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
August 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4623413-most-and-least-shorted-mid-to-mega-cap-healthcare-stocks-at-the-end-of-july
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
August 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2966652/4-biotech-stocks-likely-to-outpace-q2-earnings-estimates?cid=cs-stocknewsapi-ft-earnings_esp-2966652
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts
August 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938911
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Analysts
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tango-therapeutics-inc-nasdaqtngx-given-average-recommendation-of-moderate-buy-by-analysts-2026-08-03/
Perceptive Advisors LLC Has $16.91 Million Stock Holdings in Tango Therapeutics, Inc. $TNGX
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-has-1691-million-stock-holdings-in-tango-therapeutics-inc-tngx-2026-08-02/
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tango-therapeutics-inc-tngx-stock-holdings-trimmed-by-janus-henderson-group-plc-2026-08-02/
DV Trading LLC Takes $6.29 Million Position in Tango Therapeutics, Inc. $TNGX
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dv-trading-llc-takes-629-million-position-in-tango-therapeutics-inc-tngx-2026-08-02/
Stempoint Capital LP Acquires Shares of 200,919 Tango Therapeutics, Inc. $TNGX
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-acquires-shares-of-200919-tango-therapeutics-inc-tngx-2026-07-30/
ADAR1 Capital Management LLC Sells 90,021 Shares of Tango Therapeutics, Inc. $TNGX
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-sells-90021-shares-of-tango-therapeutics-inc-tngx-2026-07-30/
Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tango-therapeutics-tngx-to-release-quarterly-earnings-on-tuesday-2026-07-28/
Tango Therapeutics, Inc. $TNGX Shares Sold by Siren L.L.C.
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tango-therapeutics-inc-tngx-shares-sold-by-siren-llc-2026-07-24/
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958172/how-much-upside-is-left-in-tango-therapeutics-tngx-wall-street-analysts-think-49-48?cid=cs-stocknewsapi-ft-tale_of_the_tape|consensus_price_target-2958172
Tango Therapeutics, Inc. $TNGX is Trv Gp Iv LLC's 2nd Largest Position
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tango-therapeutics-inc-tngx-is-trv-gp-iv-llcs-2nd-largest-position-2026-07-21/
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 6.1% - Time to Buy?
July 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tango-therapeutics-nasdaqtngx-stock-price-up-61-time-to-buy-2026-07-17/
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
July 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tango-therapeutics-tngx-benefit-vopimetostat-140154913.html
JPMorgan Chase & Co. Initiates Coverage on Tango Therapeutics (NASDAQ:TNGX)
July 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-initiates-coverage-on-tango-therapeutics-nasdaqtngx-2026-07-15/
Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.7% - Here's What Happened
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tango-therapeutics-nasdaqtngx-shares-down-87-heres-what-happened-2026-07-13/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
A gloved hand holds a white capsule pill in a pharmaceutical laboratory setting.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
By Jeffrey Neal Johnson | July 13, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$255.41 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$255.96 +0.55 (+0.21%)
As of 08:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$84.48 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$86.49 +2.01 (+2.38%)
As of 09:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$54.07 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$54.55 +0.48 (+0.89%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$27.07 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$26.80 -0.27 (-1.02%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas